IVA vs. RENB, GBIO, SBTX, ABEO, MACK, SPRB, OPTN, ALIM, OVID, and VRCA
Should you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Renovaro (RENB), Generation Bio (GBIO), Silverback Therapeutics (SBTX), Abeona Therapeutics (ABEO), Merrimack Pharmaceuticals (MACK), Spruce Biosciences (SPRB), OptiNose (OPTN), Alimera Sciences (ALIM), Ovid Therapeutics (OVID), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical preparations" industry.
Inventiva (NASDAQ:IVA) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment.
Renovaro has lower revenue, but higher earnings than Inventiva.
Inventiva presently has a consensus target price of $16.00, indicating a potential upside of 266.97%. Given Inventiva's higher possible upside, equities research analysts plainly believe Inventiva is more favorable than Renovaro.
Inventiva has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500.
Inventiva received 13 more outperform votes than Renovaro when rated by MarketBeat users.
11.5% of Inventiva shares are held by institutional investors. Comparatively, 7.2% of Renovaro shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 21.7% of Renovaro shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Inventiva's return on equity of 0.00% beat Renovaro's return on equity.
In the previous week, Inventiva had 2 more articles in the media than Renovaro. MarketBeat recorded 6 mentions for Inventiva and 4 mentions for Renovaro. Renovaro's average media sentiment score of 0.94 beat Inventiva's score of 0.42 indicating that Renovaro is being referred to more favorably in the news media.
Summary
Inventiva beats Renovaro on 10 of the 12 factors compared between the two stocks.
Get Inventiva News Delivered to You Automatically
Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Inventiva Competitors List
Related Companies and Tools